DSCO / Dr Praveen
Well I would say that it looks good in that the product is coming from deep pockets; also, there is some evolution happening, in that inferior versions are being put aside.
Apart from that I have a very big position in DSCO - their FDA approval seems assured, and the rest is like a call-option - and no competition to speak of.
Pity the CEO pays himself so much, and then screws up. There will be finsncings from time to time too.
Market Data 
Markets 
AI
